Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040191 | 1.00 | SPHK1 (0.48) | SPHK1HSD11B2TDP1BRD4CYP4F2 | |
| SCHEMBL8053046 | 1.00 | SPHK1 (0.48) | SPHK1HSD11B2TDP1BRD4CYP4F2 | |
| SCHEMBL16053956 | 0.99 | SPHK1 (0.50) | SPHK1HSD11B2TDP1BRD4CYP4F2 | |
| SCHEMBL7305261 | 0.96 | SPHK1 (0.49) | SPHK1HSD11B2TDP1BRD4CYP4F2 | |
| SCHEMBL6208002 | 0.96 | SPHK1 (0.49) | SPHK1HSD11B2TDP1BRD4CYP4F2 | |
| SCHEMBL6208006 | 0.96 | SPHK1 (0.49) | SPHK1HSD11B2TDP1BRD4CYP4F2 | |
| SCHEMBL1068504 | 0.91 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL15318844 | 0.91 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1068506 | 0.91 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL18959562 | 0.90 | SPHK1 (0.60) | SPHK1HSD11B2BRD4NR1H2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| WO-2009081959-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDO[2,1-C][1,4]OXAZIN-6-ONE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | PSEN1, APP, BACE1 | SPHK1 253/4885HSD11B2 368/4885TDP1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.